Clinical Trial Update: AMT-253 in Patients With Advanced Solid Tumours [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of AMT-253 in patients with malignant melanoma and other advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma

Drugs mentioned

• AMT-253 (AMT-253)

Snippet

Sponsor: Multitude Therapeutics Inc. | Conditions: Malignant Melanoma, Advanced Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING